R. Mark L. Buller, Ph.D.
Professor

Ph.D., Institute of Virology
Glasgow, Scotland, 1976
bullerrm@slu.edu
Grants(1993 to present):

ONGOING

N01-AI-15436 (PI) 05/01/01-04/30/08
NIH/NIAID
Small Animal Models of human Orthopoxvirus Infections for Evaluation of Experimental Therapies
To test antivirals against orthopoxviruses virulent for mice and rabbits.

R01 AI44458 (Co-investigator) 09/30/98-05/31/06
NIH/NIAID
Mechanisms of Virus-induced Beta Cell Damage
The major goal of this project is to study the viral induction of insulin dependent diabetes mellitus. Dr. Buller will provide expertise on the various viruses that are used in the project.

U01 AI-54694 (Co-investigator) 03/15/03-02/29/05
NIH/NIAID
Contract to Elusys
Heteropolymer System to treat vaccinia complications
The broad long-term objective of the project is to develop bispecific antibodies (Heteroploymers) for treatment of complications associated with the administration of smallpox vaccine.

U01 AI-057233 (Co-investigator) 09/01/03-02/28/08
NIH/NIAID Contract to Chimerix
Development of an oral drug for smallpox treatment
The major goal is to develop preclinical data, a GMP production facility, and carryout phase 1 and phase 2 testing for prodrugs based on cidofovir.

U54 AI-057160 (Core Director)(WU Sub-contract) 09/04/03-02/29/08
NIH/NIAID
Midwest Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research (MRCE)
The goal of our portion of the Center grant is to provide small animal model development for NIAID category A agents especially variola virus and yersinia pestis. We will focus on developing respiratory infection models for basic research and for testing of anti-microbials and vaccines.


R03-AI053718-01 (Juniata College Sub-Contract) 08/15/03-07/31/05
NIH/NIAID
Immunoproteomics and detection of viral disease
The long term goal is to detect early markers of virus infection.


R21-AI061512-01 (PI) 07/01/04-06/30/06
NIH/NIAID
Study of monkeypox virus in rodents
The goal of the project is to develop a small animal model to study monkeypox virus pathogenesis. The model may have utility for the study of the efficacy of antivirals and vaccines against smallpox and human monkeypox.


COMPLETED

U01 AI-48653 (PI) 09/27/00-08/31/04
NIAID
Orthopoxvirus Genomics and Bioinformatics Resource Center
To construct a resource center for data and reagents that will facilitate the development of improved vaccines and anti-virals against human orthopoxvirus infections.

R21 AI-53346 (PI) 09/01/02-08/31/04
NIH/NIAID
Immunodominant epitopes of a smallpox vaccine in humans
The major goal of this project is to identify the viral protein epitopes recognized by the human immune system.


Subcontract to Acambis (Co-investigator) 03/01/01- 02/28/02
CDC
Comparison of the Dryvax Calf Lymph and OraVax Tissue Culture NYCBH Strains of vaccinia Virus
Using various approaches the disease potential of the current smallpox vaccine, Dryvax, was compared to the candidate replacement, the OraVax vaccine.

2 R42 AI42431-02A1 (PI) 08/01/00-12/28/02
NIAID (STTR) Program
Virus cytokine binding proteins in rapid cytokine assays.
The major goal of this project was the development of new assays for cytokine detection.